创新药物研发--拜耳先灵医药的发展方式  

Research and development of new drugs,the ways of Bayer Schering Pharma

作　　者：Andreas Busch 

机构地区：[1]拜耳先灵医药

出　　处：《中国新药杂志》2009年第17期1597-1601,共5页Chinese Journal of New Drugs

摘　　要：拜耳先灵医药全球研发部(GDD)的使命是用小分子和生物类创新药物来改善患者生活质量,关注心脏病、肿瘤、诊断影像和女性健康这四个领域内未被满足的医疗需求。在研究与开发活动中,与清华大学这样的顶级科研组织进行全球性创新合作是很重要的一部分。在研发所在地拥有整合性技术平台能够保证操作流程优化,这对于达到质量高标准和减少药品研发价值链损耗是必要的。通用机制协同效应会最大化在癌症、心脏病和女性健康方面候选药品的价值。最近实验室的成功案例是抗癌药物多吉美(索拉非尼)和口服抗凝药拜瑞妥(利伐沙班)。生物制药也是拜耳先灵医药的核心领域,各种项目正在向前推进,如靶向抗癌放射免疫疗法L19-SIP,以及做为分子影像工具的Florbetaben,能够在阿尔茨海默病早期在体内检测大脑β样淀粉酶斑块。成立"国际研发中心(中国)",以及"拜耳-清华创新药研究中心"就是为了完成拜耳先灵医药使命的最新举措。The Mission of the Global Drug Discovery（GDD） organization at Bayer Schering Pharma is to improve the quality of life for patients with innovative medicines-small molecules and biologics.Our organization is focusing on specialty indications of high unmet medical need within the four therapeutic areas cardiology,oncology,diagnostic imaging and women＇s healthcare.Global innovation networks with top tier research organizations such as the Tsinghua University play a central role for our research and development activities.Integrated technology platforms at our research sites ensure the operational excellence which is needed in order to meet highest quality standards and to tackle attrition within the drug R＆D value chain.Common mechanism synergies maximize the value of our drug candidates for patients across our research areas cancer,cardiology and Women＇s Healthcare.Recent success stories from our laboratories are the anti-cancer drug Nexavar（Sorafenib） and the orally active anticoagulant Xarelto（rivaroxaban）.As also biologics are of central importance for BSP,various projects in this area are currently moving forward,such as the L19-SIP for targeted anti-cancer radioimmuno therapy and Florbetaben as a molecular imaging tool to facilitate in vivo detection of β-amyloid plaques in the brain at an early stage of Alzheimer Disease.The ＂GDD Innovation Center China＂ and the joint ＂Bayer-Tsinghua Center for Innovative Drug Discovery＂ are new approaches to fulfill our mission.

关 键 词：拜耳先灵医药 创新药物 研发 

分 类 号：R95[医药卫生—药学]